HomeCompareFREQ vs GBDC

FREQ vs GBDC: Dividend Comparison 2026

FREQ yields 667.56% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FREQ wins by $614781.21M in total portfolio value
10 years
FREQ
FREQ
● Live price
667.56%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$614802.06M
Annual income
$474,868,230,549.69
Full FREQ calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — FREQ vs GBDC

📍 FREQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFREQGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FREQ + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FREQ pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FREQ
Annual income on $10K today (after 15% tax)
$56,742.32/yr
After 10yr DRIP, annual income (after tax)
$403,637,995,967.24/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, FREQ beats the other by $403,624,012,843.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FREQ + GBDC for your $10,000?

FREQ: 50%GBDC: 50%
100% GBDC50/50100% FREQ
Portfolio after 10yr
$307411.45M
Annual income
$237,442,340,641.77/yr
Blended yield
77.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

FREQ
Analyst Ratings
3
Buy
4
Hold
Consensus: Hold
Price Target
$1.40
+367.3% upside vs current
Range: $1.40 — $1.40
Altman Z
-7.4
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FREQ buys
0
GBDC buys
0
No recent congressional trades found for FREQ or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFREQGBDC
Forward yield667.56%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$614802.06M$20.85M
Annual income after 10y$474,868,230,549.69$16,450,733.83
Total dividends collected$603369.48M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy
Analyst price target$1.40$14.00

Year-by-year: FREQ vs GBDC ($10,000, DRIP)

YearFREQ PortfolioFREQ Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$77,456$66,755.67$12,492$1,791.70+$65.0KFREQ
2$566,112$483,234.18$16,527$3,160.58+$549.6KFREQ
3$3,906,567$3,300,827.31$23,588$5,904.90+$3.88MFREQ
4$25,467,892$21,287,865.51$37,141$11,901.65+$25.43MFREQ
5$156,952,466$129,701,821.96$66,205$26,463.38+$156.89MFREQ
6$914,968,107$747,028,968.25$137,452$66,612.65+$914.83MFREQ
7$5,048,988,394$4,069,972,519.36$342,372$195,298.53+$5048.65MFREQ
8$26,392,111,970$20,989,694,387.90$1,053,292$686,954.33+$26391.06MFREQ
9$130,779,275,796$102,539,715,988.68$4,111,439$2,984,416.95+$130775.16MFREQ
10$614,802,055,652$474,868,230,549.69$20,849,974$16,450,733.83+$614781.21MFREQ

FREQ vs GBDC: Complete Analysis 2026

FREQStock

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Full FREQ Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this FREQ vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FREQ vs SCHDFREQ vs JEPIFREQ vs OFREQ vs KOFREQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.